Clinical Trial

A Phase 1, First-in-human Study of VX-433

Name: A Phase 1, First-in-human Study of VX-433 — clinical trial record (NCT07584434)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-09

Trial Details

NCT Number	NCT07584434
Lead Sponsor	Vertex Pharmaceuticals Incorporated
Conditions	Narcolepsy Type 1 (NT1)
Enrollment	118 participants
Start Date	2026-05-21
Primary Completion	2027-03-05 (estimated)
Study Completion	2027-03-05 (estimated)
Updated on ClinicalTrials.gov	2026-06-08